Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00555412 · ClinicalTrials.gov registry record · Phase 1
Staccato Loxapine Multidose PK
A Phase 1 study, sponsored by Alexza Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00555412 is a Phase 1 study that has completed, run by Alexza Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT00555412, a Phase 1 study, has completed, sponsored by Alexza Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The objectives of this trial are to assess the safety, tolerability, and pharmacokinetics of multiple inhaled doses of Staccato Loxapine.
Interventions
- DRUG A - 10 mg loxapine q 4 h x 3 (30 mg total)
- DRUG B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)
- DRUG C - 5 mg loxapine q 4 h x 3 (15 mg total)
- DRUG D - inhaled placebo q 4 h x 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-10 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00555412
The ClinicalTrials.gov registry entry for NCT00555412 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexza Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which A - 10 mg loxapine q 4 h x 3 (30 mg total) is the first listed.
NCT00555412 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00555412 about?
NCT00555412 is a clinical study titled "Staccato Loxapine Multidose PK". The objectives of this trial are to assess the safety, tolerability, and pharmacokinetics of multiple inhaled doses of Staccato Loxapine.
What is the current status of trial NCT00555412?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2007-10. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00555412?
The interventions under investigation include: A - 10 mg loxapine q 4 h x 3 (30 mg total) (DRUG), B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total) (DRUG), C - 5 mg loxapine q 4 h x 3 (15 mg total) (DRUG), D - inhaled placebo q 4 h x 3 (DRUG).
Who is sponsoring clinical trial NCT00555412?
This trial is sponsored by Alexza Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.